Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

1.8K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
1.8K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

5.5K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
5.5K
Cancer Vaccines01:30

Cancer Vaccines

972
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
972
Cytotoxic T Cells-mediated Immune Response01:27

Cytotoxic T Cells-mediated Immune Response

6.5K
Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
6.5K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.6K
The Intrinsic Apoptotic Pathway01:31

The Intrinsic Apoptotic Pathway

8.3K
Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
8.3K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Author Correction: SLAMF6 as a drug-targetable suppressor of T cell immunity against cancer.

Nature·2026
Same author

SLAMF6 as a drug-targetable suppressor of T cell immunity against cancer.

Nature·2026
Same author

Targeting phagocytosis checkpoints for cancer immunotherapy.

Nature reviews. Cancer·2025
Same author

Anticancer immune responses are hindered by cis interaction of inhibitory checkpoint SIRPα.

Science immunology·2025
Same author

CD2 and its ligands are involved in development and activation of MAIT cells.

The Journal of experimental medicine·2025
Same author

CD47 masks pro-phagocytic ligands in cis on tumor cells to suppress antitumor immunity.

Nature immunology·2023
Same journal

Erratum for the Research Article "Claudins interact with LILRB immune inhibitory receptors to promote myeloid immunosuppression in cancer".

Science immunology·2026
Same journal

Langerhans cell control of early-life dermal lymphatic development shapes adult immunity.

Science immunology·2026
Same journal

T<sub>reg</sub> cells promote immunotherapy-induced immune evasion by restraining CD4 T cell control of MHC-I-deficient metastatic pancreatic cancer.

Science immunology·2026
Same journal

CXCL16-mediated recruitment of γδ T cells to the brain reduces sociability in mice.

Science immunology·2026
Same journal

Bioactive enhanced adjuvant chemokine oligonucleotide nanoparticles (BEACONs) for mucosal vaccination against genital herpes.

Science immunology·2026
Same journal

Bacterial infection reshapes monocyte and macrophage ontogeny at the CNS borders.

Science immunology·2026
See all related articles

Related Experiment Video

Updated: Jan 16, 2026

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology
07:04

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Published on: May 2, 2025

1.1K

Inhibitory immune checkpoints in cancer immunotherapy.

Zhenghai Tang1,2, André Veillette3,4,5

  • 1Cancer Center, Faculty of Health Sciences, University of Macau, Macau, SAR, China.

Science Immunology
|September 26, 2025
PubMed
Summary
This summary is machine-generated.

Immune checkpoint inhibitors like PD-1 and CTLA-4 show variable cancer treatment efficacy. Further research is needed to understand complex mechanisms for developing safer and more effective immunotherapies.

More Related Videos

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells
09:04

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells

Published on: March 7, 2025

1.5K
Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine
09:15

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Published on: February 24, 2023

3.9K

Related Experiment Videos

Last Updated: Jan 16, 2026

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology
07:04

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Published on: May 2, 2025

1.1K
Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells
09:04

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells

Published on: March 7, 2025

1.5K
Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine
09:15

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Published on: February 24, 2023

3.9K

Area of Science:

  • Immunology
  • Oncology
  • Pharmacology

Background:

  • Immune checkpoint inhibitors targeting PD-1 and CTLA-4 have revolutionized cancer therapy but exhibit limited efficacy in certain cancers.
  • Variable patient responses and emerging complexities necessitate exploration of additional immune checkpoints as therapeutic targets.

Purpose of the Study:

  • To review the complexities of inhibitory immune checkpoints beyond PD-1 and CTLA-4.
  • To provide insights for developing more effective and safer immunotherapies.

Main Methods:

  • Literature review of recent studies on immune checkpoint inhibitors.
  • Analysis of mechanisms of action and regulation of experimental inhibitory immune checkpoints.

Main Results:

  • Current immune checkpoint inhibitors have limitations in efficacy and patient variability.
  • Experimental checkpoints and their targeting drugs display unexpected or undesirable mechanisms of action.
  • Underappreciated complexities in immune checkpoint regulation impact therapeutic outcomes.

Conclusions:

  • A deeper understanding of immune checkpoint intricacies is crucial for advancing cancer immunotherapy.
  • Future therapeutic strategies must address these complexities to improve treatment effectiveness and safety.